% alzhub.org library filter
% Source: https://alzhub.org/research?category=imaging&atag=monoclonal
% 6 entries, in the order the page lists them. Built from alzhub.org's own records.
% 0 entries have no readable author in the source record and carry no author field.

@article{lowe2021-34585215,
  author  = {Lowe, S L and Evans, C Duggan and Shcherbinin, S and Cheng, Y-J and Willis, B A and Gueorguieva, I and Lo, A C and Fleisher, A S and others},
  title   = {{Donanemab (LY3002813) Phase 1b Study in Alzheimer's Disease: Rapid and Sustained Reduction of Brain Amyloid Measured by Florbetapir F18 Imaging}},
  journal = {The journal of prevention of Alzheimer's disease},
  year    = {2021},
  doi     = {10.14283/jpad.2021.56},
  pmid    = {34585215},
  url     = {https://doi.org/10.14283/jpad.2021.56}
}

@article{sperling2023-37458272,
  author  = {Sperling, R. A. and Donohue, M. C. and Raman, R. and Rafii, M. S. and Johnson, K. and Masters, C. L. and van Dyck, C. H. and Iwatsubo, T. and others},
  title   = {{Trial of Solanezumab in Preclinical Alzheimer's Disease}},
  journal = {The New England journal of medicine},
  year    = {2023},
  doi     = {10.1056/nejmoa2305032},
  pmid    = {37458272},
  url     = {https://doi.org/10.1056/nejmoa2305032}
}

@article{otomi2026-42507054,
  author  = {Otomi, Yoichi and Shinya, Takayoshi and Otsuka, Hideki and Kasai, Hiroto and Matsushita, Tomoki and Takaoka, Yukiko and Hiroshima, Yuka and Matsubara, Tomoyasu and others},
  title   = {{Serial amyloid PET demonstrates marked reduction in amyloid burden following donanemab treatment: a real-world cohort study}},
  journal = {Japanese journal of radiology},
  year    = {2026},
  doi     = {10.1007/s11604-026-02054-x},
  pmid    = {42507054},
  url     = {https://doi.org/10.1007/s11604-026-02054-x}
}

@article{rezai2024-38169490,
  author  = {Rezai, A. R. and D'Haese, P. F. and Finomore, V. and Carpenter, J. and Ranjan, M. and Wilhelmsen, K. and Mehta, R. I. and Wang, P. and others},
  title   = {{Ultrasound Blood-Brain Barrier Opening and Aducanumab in Alzheimer's Disease}},
  journal = {The New England journal of medicine},
  year    = {2024},
  doi     = {10.1056/nejmoa2308719},
  pmid    = {38169490},
  url     = {https://doi.org/10.1056/nejmoa2308719}
}

@article{cummings2024-37955845,
  author  = {Cummings, J. and Osse, A. M. L. and Cammann, D. and Powell, J. and Chen, J.},
  title   = {{Anti-Amyloid Monoclonal Antibodies for the Treatment of Alzheimer's Disease}},
  journal = {BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy},
  year    = {2024},
  doi     = {10.1007/s40259-023-00633-2},
  pmid    = {37955845},
  url     = {https://doi.org/10.1007/s40259-023-00633-2}
}

@article{boxer2023-37848035,
  author  = {Boxer, A. L. and Sperling, R.},
  title   = {{Accelerating Alzheimer's therapeutic development: The past and future of clinical trials}},
  journal = {Cell},
  year    = {2023},
  doi     = {10.1016/j.cell.2023.09.023},
  pmid    = {37848035},
  url     = {https://doi.org/10.1016/j.cell.2023.09.023}
}